Letters Bevacizumab for retinal disorders Macular degeneration needs longer lasting treatments BMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g7524 (Published 10 December 2014) Cite this as: BMJ 2014;349:g7524 Article Related content Metrics Responses Peer review Related articles Editorial What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders? Published: 19 November 2014; BMJ 349 doi:10.1136/bmj.g6887 See more The BMJ Christmas appeal 2016-7: Orbis, the sight savers BMJ December 01, 2016, 355 i6425; DOI: https://doi.org/10.1136/bmj.i6425 Leaps in the dark BMJ December 01, 2016, 355 i6447; DOI: https://doi.org/10.1136/bmj.i6447 NHS spent 8% more on medicines last year BMJ November 23, 2016, 355 i6320; DOI: https://doi.org/10.1136/bmj.i6320 Seven days in medicine: 9 to 15 November 2016 BMJ November 17, 2016, 355 i6106; DOI: https://doi.org/10.1136/bmj.i6106 Babies with microcephaly in Brazil are struggling to access care BMJ November 16, 2016, 355 i6157; DOI: https://doi.org/10.1136/bmj.i6157
